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ABSTRACT 
Two contrasting patients are described, one with pseudo- 
Bartter's syndrome induced by frusemide abuse and the other 
a case of hyporeninaemic hypoaldosteronism. 
The clinical and biochemical features of these two 
conditions are the opposite of each other and, in the first 
patient, the effects of frusemide were antagonised by 
treatment with indomethacin while in the second frusemide 
itself corrected the syndrome. 
The decreased pressor sensitivity to infused angiotensin II 
seen in the patient with pseudo-Bartter's syndrome was 
corrected with indom.ethacin and the enhanced pressor 
sensitivity seen in hyporeninaemic hypoaldosteronism was 
reversed with frusemide. 
Frusemide, an agent which blocks chloride transport at the 
ascending limb of Henle's loop, was respectively thus the 
cause and the cure of these conditions. On the basis of 
this the suggestion is made that Bartter's syndrome and 
hyporeninaemic hypoaldosteronism represent respectively an 
excess and a deficiency of a circulating factor similar to 
frusemide capable of blocking renal tubular chloride 
transport. 
INTRODUCTION 
Bartter's syndrome (1) and hyporeninaemic hypoaldosteronism 
(2) are two uncommon conditions whose aetiologies are 
unknown. The features of Bartter's syndrome can be closel:y 
mimicked in patients who abuse diuretics, particularly loop 
diuretics (3-7), and there is evidence to suggest that the 
biochemical defects of hyporeninaemic hypoaldosteronism. can 
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be corrected or improved by the long-term administration of 
diuretics (8-11). Many of the biochemical features of 
these two conditions are the exact opposite of each other 
and we have recently suggested (12) that they may represent 
opposite abnormalities of chloride reabsorption at the 
thick ascending limb of Henle's loop. We further argued 
(12) that rather than there being a structural renal 
abnorr.ality in these conditions they represented an excess 
(Bartter's syndrome) and a deficiency (hyporeninaenic 
hypoaldosteronism) of a circulating factor capable of 
inhibiting chloride transport. This current report 
describes studies in two patients which provide 
circumstantial evidence for the validity of this hypothesis. 
CASE REPORTS 
Case 1 
A 53 year old hypertensive Caucasian female was first seen 
at the University of Michigan Hospital in January 1979 when 
she was reportedly taking methyldopa 1500 mg/d together 
with spironolactone 200 mg/d and potassium supplements 200 
mmol/d because of previous hypokalaemia. Physical 
examination was unremarkable, blood pressure 150/92 mmHg 
an& serum potassium 2.6 mmol/l. After discontinuation of 
all therapy for one month, the patient was admitted to the 
Clinical Research Center for a three week period during 
which sodium and potassium intakes were fixed at 130 and 
150 mmol/d respectively. In addition to investigations 
outlined in Figure 1, on three occasions (days 5, 16 and 
22), after overnight fast and recumbency, the patient 
underwent incremental infusions of anqiotensin II 
(Hypertensin - CIBA) to assess pressor sensitivity (13). 
Serum sodium remained essentially unchanged throughout the 
period of study (Fig 1). Serum potassium was normal (3.7 
mmol/l) on admission but fell rapidly during the period 
before institution of indomethacin (2.5 nunol/l). During 
treatment with indor,ethacin, serum potassium increased 
progressively to a maximum of 3.6 mmol/l but fell again on 
withdrawal of the drug (2.7 mmol/l). Sodium balance did 
not appear to be achieved prior to indomethacin treatment 
and was progressively positive thereafter (Fig 1). 
Potassium balance also appeared persistently positive 
(see Discussion). 
Despite the observed sodium balance data, changes in weight 
closely paralleled serum potassium, there being an initial 
fall followed by an increase during indomethacin therapy 
(Fig 1). The fall in weight seen between the third and 
seventh day of indomethacin therapy prompted the increase 
in the dose from 150 to 200 rig/d which was immediately 
followed by further weight gain. There was a rapid fall 
in weight after stopping treatment. Blood pressure rose 
during treatment with indomethacin (132/86 to 164/98 mmHg) 










Figure 1 Case I: Changes in body weight, PFW, 
angiotensin II and aldosterone together with sodium and 
potassium balance. Indomethacin was administered between 
day 6 and 16. 
PAIIc = plasma angiotensin II concentration, 
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Changes in PRA (14), angiotensin II (15) and aldosterone 
(16) can be seen to closely parallel each other and to 
occur in opposite directions to change in weight, blood 
pressure and serum potassium (Fig 1). Indomethacin therapy 
returned PM, angiotensin II and aldosterone levels to 
normal. Plasma volume (Evans Blue dilution) increased from 
1982 ml to 2277 ml over the period of indomethacin therapy. 
The dose response curve relating changes in circulating 
venous angiotensin II to changes in mean blood pressure was 
displaced far to the right of that seen in normal human 
volunteers on similar sodium intakes (13), i.e. the blood 
pressure response was diminished. Treatment with 
indomethacin caused a shift to the left of the dose 
response curve which approximated to that seen in normal 
subjects on a normal sodium intake: after stopping 
indomethacin the dose response curve returned towards that 
seen in the basal state (Fig 2). 








Figure 2 Case I: The relationship of change of mean blood 
pressure (diastolic + one third of oulse cressure) to 
venous plasma levels of angiotensin II during angiotensin 
II infusion. Lines R and D represent the mean responsive- 
ness of normal subjects studied in an identical fashion on 
sodium replete and deplete intakes respectively (13). 
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Aliquots of urine from days 3, 9 and 11 of the study 
(chosen because of increased sodium content - see Fig 1) 
were analysed qualitatively for frusemide. This was found 
in all samples of urine and a quantitative assessment from 
the urine on day 3 revealed 6.3 pg/ml. 
Case 2 
A 54 year old diabetic hypertensive black male had been 
noted to be hyperkalaemic (7.3 mmol/l) during an episode 
of deterioration of diabetic control. Serum potassium had 
fallen with lowering of the blood sugar and plasma 
aldosterone was low at 2.2 ng/dl together with a low 
urinary aldosterone excretion (1.1 ug/24 h (normal 2-20)). 
A provisional diagnosis of hyporeninaemic hypoaldosteronism 
was made and after discontinuing methyldopa for four weeks 
the patient was admitted to the Clinical Research Center. 
Insulin therapy was continued unchanged throughout all 
studies. 
Apart from hypertension and diminished foot pulses, the 
only significant abnormality was the presence of mild 
background diabetic retinopathy. Serum creatinine varied 
between 180 and 250 mmol/l. Blood sugar was well 
controlled throughout admission (~6.5 mmol/l). Possibly 
because of the absence of hyperglycaemia the patient was 
never frankly hyperkalaemic (4.2-5.6 mmol/l) . Sodium (130 
mmol/d) and potassium (90 mmol/d) were kept constant during 
the first four days of admission and thereafter sodium 
intake was decreased to 10 nunol/d preceded by an 
intravenous bolus of 40 mg frusemide to enhance sodium 
depletion. On the fourth day of normal sodium intake, 
pressor sensitivity to infused angiotensin II was assessed. 
The patient was discharged on oral frusemide, the dose of 
which was increased as an outpatient till a repeat 
admission three months later for an identical study, 
although oral frusemide was continued throughout. 
During the first admission basal levels of PRA, angiotensin 
II and aldosterone were low on a normal sodium intake, with 
only a sluggish response to three days of salt restriction 
(Fig 3). Sodium balance was not quite achieved during this 
period, urine sodium falling to 16 mmol/d after three days. 
During the second admission, after the patient had 
increased his frusemide (on his own volition) to 480 mg/d, 
serum potassium (4.3-4.9 mmol/l) was not significantly 
different from the earlier admission. PRA, angiotensin II 
and aldosterone were all increased to levels seen during 
salt depletion in normal subjects (Fig 3). Acute salt 
depletion produced a brisk increase in all indices (Fig 3), 
urine sodium decreasing only to 55 mmol/d. 
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EFFECT of ACUTE SODIUM DEPLETION on RENIN 
ANGIOTENSIN a and ALDOSTERONE 
Aldosterone 
rig/d’’ 20 I 
0-O Control 
After 
o----o Ch ronic Frusemide 
Angiotensin II 
pglml 
Normal No+ Low No+ 
Figure 3 Case II; The effect of acute sodium depletion 
of PRA, angiotensin II and aldosterone before (o -0) and 
during long term frusemide administration (O---O). Normal 
ranges shown in cross hatching. 
Basal blood pressure on the morning of the angiotensin II 
infusion during the first admission was 152/100 mmHg. 
Infusion of 2 mg/kg/min of angiotensin II produced a marked 
rise of blood pressure to 170/116 mmHg (Fig 4). While 
increasing the infusion rate to 4 mg/kg/min, blood pressure 
rose to 198/134 mmHg within five minutes and the infusion 
was terminated without further blood sampling. In 
comparison with normal subjects (Fig 4) this represents a 
markedly increased pressor response. During the second 
admission, following long term frusemide therapy, basal 
blood pressure was lower at 132/88 mmHg. The blood 
pressure response to infused angiotensin II was much 
reduced, the dose response curve of venous angiotensin II 
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against changes in mean blood pressure was shifted to 
right and approximated to that seen in sodium replete 
normal subjects (Fig 4). 





Control (2ng/kg/min only) 
Furoremide(2-8ng/kg/min) 





f’. AZ pg/ml 
Figure 4 Case II; Relationship of changes in mean blood 
pressure to plasma levels of anqiotensin II during 
angiotensin II infusions. Lines R and D represent normal 
subjects similarly infused on low and normal salt intakes 
respectively. 
DISCUSSION 
Our first patient caused some initial confusion because of 
the discrepant urinary electrolyte results seen throughout 
her studies. In view of the subsequent discovery that she 
was taking frusemide it seems likely that she was not 
consuming the whole of her dietary intake to explain an 
apparent positive potassium balance. 
'The two patients described have biochemical defects which 
are opposite to one another: the first patient (although 
supposedly being treated for hypertension) had a near 
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normal blood pressure and a persistent hypokalaemic 
alkalosis. She had markedly increased circulating levels 
of PRA, angiotensin II and aldosterone with a diminished 
pressor sensitivity to infused angiotensin II. The second 
patient (a diabetic with mildly impaired renal function) 
had elevated blood pressure and intermittent hyperk.alaemia 
with mild acidosis. Plasma renin activity, angiotensin II 
and aldosterone were all low and relatively unresponsive to 
acute stimulatory manoeuvres. The pressor sensitivity to 
infused angiotensin II was dramatically increased. In the 
first case the abnormalities described were caused by the 
surreptitious abuse of frusemide. In the second, 
therapeutic use of the same drug corrected opposite 
abnormalities. 
Bartter's syndrome has as its essential characteristics 
hypokalaemic alkalosis, increased plasma levels of renin, 
angiotensin II and often aldosterone, together with 
juxtaglomerular cell hyperplasia of the kidney. Patients 
are normotensive but display a marked insensitivity to the 
pressor effects of infused angiotensin II (17). The 
proximal cause for this constellation of biochemical 
features remains uncertain. The demonstration of increased 
production of renal prostaglandins (18-22) together with 
the correction of many of the features of this syndrome 
with the use of prostaglandin synthetase inhibitors (18-21, 
23-25) led many to suppose that excessive prostaglandin 
production was the cause of the condition. However, long 
term therapy with indomethacin, while correcting the 
hypereninaemia and the hyporesponsiveness to the pressor 
effects of infused angiotensin II, does not fully correct 
the renal loss of potassium or the hypokalaemia (24) 
suggesting that potassium loss m.ight be the cause rather 
than the effect of excessive prostaglandin production (26, 
27). The suggestion that chloride reabsorption at the 
ascending limb of Henle's loop (3) might be defective in 
this condition was confirmed by Gill and Bartter (28) and a 
defect at this site in the renal tubule appears at the 
moment to be the most likely cause of Bartter's syndrome. 
Chloride is known to be actively transported at the 
ascending limb of Henle's loop (29,30) which is the site at 
which loop diuretics act to block chloride transport (31). 
Self administration of diuretics can indice a clinical 
state virtually indistinguishable from Bartter's syndrome 
(3,7) including juxtaglomerular cell hyperplasia (4,7). 
Frusemide administration is also known to increase urinary 
prostaglandin E2 (32,33). The marked similarity between 
Bartter's syndrome and the effects of frusemide as 
demonstrated in our patient, together with the normalising 
of all biochemical abnormalities with indomethacin therapy, 
allow us to suggest the possibility that an excess of a 
circulating factor similar to frusemide might be 
responsible for Bartter's syndrome. There is in fact 
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evidence of a more generalised defect in Bartter's syndrome 
including altered membrane sodium transport (34,35) and a 
defect in platelet aggregation (36) implying that there is 
more than a single renal abnormality in this condition. 
In terms of clinical and biochemical features the condition 
most directly opposite to that of Bartter's syndrome is 
that condition first described in 1964 by Paver and Pauline 
(37), sometimes referred to as Gordon's syndrome (38) and 
most recently described by Schambelan et al as type II 
pseudohypoaldosteronism (39). This condition has been 
shown to be associated with increased renal chloride 
reasborption in the distal tubule (39) and is a strong 
candidate for the mirror image of Bartter's syndrome. 
Hyporeninaemic hypoaldosteronism is a condition with 
similar biochemical features including a hyperkalaemic 
acidosis, low and unresponsive plasma levels of renin and/ 
or angiotensin II, together with low plasma or urinary 
aldosterone levels. The condition tends to occur typically 
in elderly patients with diabetes and mild renal 
insufficiency. The features of the condition have been 
extensively reviewed recently (40,41) and were apparent in 
our patient. The presence of hypertension rather than 
hypotension in the majority of cases (41) makes it unlikely 
that aldosterone deficiency consequent upon renin 
deficiency is the primary cause of this condition. The 
observation that supraphysiological doses of mineralo- 
corticoid are often needed to normalise the elevated serum 
potassium (8,10,42-48) suggests that the aldosterone 
deficiency is not the whole cause of the hyperkalaemia, and 
indeed these large doses of mineralocorticoid replacement 
often correct serum potassium levels only at the expense of 
raising blood pressure still further (10,46). 
The active reabsorption of chloride at the ascending limb 
of ilenle's loop will result in the passive reabsorption of 
both sodium and potassium giving rise to a tendency to 
hyperkalaemia in an opposite fashion to that suggested as 
the cause of hypokalaemia in Bartter's syndrome (28). It 
is known that prolonged sodium depletion (45) or long term 
therapy with diuretics (8-11) are capable of stimulating 
the production of renin and/or aldosterone while acute 
sodium depletion is not. In addition, where measured, 
patients with this condition have been shown to exhibit 
expansion of extracellular fluid volume and exchangeable 
sodium (10). These data suggest that renin suppression 
might be consequent upon volume expansion. 
Other abnormalities recently described in hyporeninaemic 
hypoaldosteronism are also biochemically opposite to those 
seen in Bartter's syndrome and tend to support our 
argument; urinary prostaglandins have been shown to be low 
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(49,50) and in susceptible individuals with renal 
insufficiency the use of indomethacin, a drug which blocks 
prostaglandin synthesis, has been associated with a 
hyperkalaemic syndrome similar to hyporeninaemic 
hypoaldosteronism (51,52). 
A mildly increased pressor sensitivity to infused 
angiotensin II has been described in essential hypertension 
(53,54) but is not a universal finding (55). The dramatic 
pressor response seen in our second patient is more like 
that described in primary hyperaldosteronism (53,56), an 
undoubted volume expanded state. The low-normal levels of 
renin/angiotensin II and aldosterone observed in our 
patient were significantly increased with long term 
diuretic therapy after a blunted acute response had been 
demonstrated. This, together with the significant fall in 
blood pressure induced by frusemide and the correction of 
increased pressor sensitivity to infused angiotensin II, 
is further strong evidence that volume expansion is an 
integral part of this syndrome. Our observation that 
frusemide corrected this syndrome argues against a 
structural renal defect as the cause of hyporeninaemic 
hypoaldosteronism, and allows us to postulate that this 
syndrome might occur in the absence of such an endogenously 
produced substance. 
Evidence presented by these patients is of necessity 
inferential and cannot prove or disprove the idea that 
there exists a circulating factor capable of affecting 
chloride transport. That there are humoral factors other 
than aldosterone which govern sodium transport by the 
kidney seems to us to be well established (57). We suggest 
that at least one of these factors might act on the 
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